# Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

> **NCT00074009** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00074009
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074009, "Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00074009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*